Our life goal is to make yours better.

CVRx® is a privately held company founded in 2001 and headquartered in Minneapolis, U.S.A. Our vision is to advance health for people everywhere, giving each patient a fuller life. CVRx® pioneers unique therapies that harness and harmonize the body's natural systems, benefiting society and making CVRx® a universal role model in healthcare.

Barostimneo

Pioneering a Unique Therapy

BAROSTIM NEO™ is the only device CE Marked for the separate indications of heart failure and resistant hypertension. Currently, BAROSTIM NEO™ is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States.

Learn More About Barostim Neo™

Our Awards

CVRx® has received numerous awards throughout the years.
Click on a logo to learn more.
Awards Section

Our History

  • 2001

    CVRx® established in Minneapolis, Minnesota, USA

  • 2004

    First patient treated with the first-generation BAROSTIM THERAPY™ device in Bern University Hospital (Switzerland)

  • 2005

    First patient treated in the US

  • 2006

    Early findings from DEBuT-HT Hypertension trial, showing significant reductions in blood pressure, are presented at the American Heart Association congress

  • 2007

    First-generation BAROSTIM THERAPY™ device receives CE-mark approval for resistant hypertension

  • 2008

    Two-year results of DEBuT-HT Hypertension trial confirm first-generation BAROSTIM THERAPY™ device’s significant blood pressure reduction

  • 2011

    Introduction of the BAROSTIM NEO™ device, which receives CE-mark approval for resistant hypertension

  • Jun 2014

    Publication of a "Proof-of-concept" study in Heart Failure concluding that BAROSTIM NEO™ is safe and provides chronic improvement to patients

  • Sep 2014

    BAROSTIM NEO™ receives CE-mark approval for the treatment of heart failure

  • Dec 2014

    BAROSTIM NEO™ LEGACY granted Humanitarian Device Exemption by FDA for Hypertensive patients who were defined as responders to the Rheos Carotid Sinus Lead System

  • May 2015

    1000 patients treated with BAROSTIM THERAPY™

  • Jun 2015

    Results of BAROSTIM THERAPY™ for Heart Failure randomized study presented at several international congresses

  • Nov 2015

    Expedited Access Pathway designation granted by FDA for BAROSTIM THERAPY™ for the treatment of heart failure

  • Jun 2016

    First patients treated in pivotal trial evaluating BAROSTIM THERAPY™ in heart failure (BeAT-HF)

Expand History
Collapse History

Leadership Team

Board of Directors

Senior Management